Kunit Thomas, Lusuardi Lukas
Department of Urology and Andrology, Paracelsus Medical University Salzburg, Salzburg, Austria.
Res Rep Urol. 2014 Jul 12;6:67-70. doi: 10.2147/RRU.S46047. eCollection 2014.
In elderly men, benign prostatic hyperplasia is often associated with lower urinary tract symptoms, and its prevalence rises with age. Lower urinary tract symptoms can be very bothersome and lead to a decrease in health-related quality of life. Furthermore, benign prostatic hyperplasia is a progressive disease that can lead to serious complications like acute urinary retention. Medical treatment with α1-blockers or 5α-reductase inhibitors is recommended by the European Association of Urology. On the other hand, there are some new innovations such as NX1207. The aim of this review is to summarize the published data. NX1207 is a new drug that is administered by transrectal intraprostatic injection under ultrasound guidance. The substance leads to prostate volume reduction and symptomatic improvement. However, patient numbers are still low and currently treatment with NX1207 is still experimental.
在老年男性中，良性前列腺增生常与下尿路症状相关，且其患病率随年龄增长而上升。下尿路症状可能非常困扰患者，并导致健康相关生活质量下降。此外，良性前列腺增生是一种渐进性疾病，可导致严重并发症，如急性尿潴留。欧洲泌尿外科学会推荐使用α1受体阻滞剂或5α还原酶抑制剂进行药物治疗。另一方面，有一些新的创新药物，如NX1207。本综述的目的是总结已发表的数据。NX1207是一种在超声引导下经直肠前列腺内注射给药的新药。该药物可使前列腺体积缩小并改善症状。然而，目前的患者数量仍然较少，NX1207治疗仍处于试验阶段。
